PARP Quiz! Strategies for Targeting DNA Repair in Prostate Cancer

Join us for this dynamic, CME-certified symposium! Celestia S. Higano, MD, FACP, and Charles J. Ryan, MD, will review the evolving role of PARP inhibitors in prostate cancer, including an overview of DNA repair deficiencies in prostate cancer, guidance on genetic testing, an update on the latest clinical data on PARP inhibitors for the treatment of prostate cancer and future directions, and case discussions of where PARP inhibitors fit into the standard of care setting.

Sign up now! Registration is complimentary.

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “PARP Quiz! Strategies for Targeting DNA Repair in Prostate Cancer” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that each Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Agenda

7:00 PM - 7:05 PM Welcome and Introduction

7:05 PM - 7:15 PM DNA Damage Repair Genes: Prevalence and Impact on Prognosis – Celestia S. Higano, MD

7:15 PM - 7:40 PM Practical Guidance on the Assessment of BRCA and Other DNA Damage Repair Genes in Prostate Cancer Celestia S. Higano, MD, FACP

7:40 PM - 8:10 PM Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors Charles J. Ryan, MD

8:10 PM - 8:25 PM  Case Discussions: Applying the Data to Practice—Therapeutic Planning for Patients With DRG Defects (BRCA1/2 or ATM Mutations) – Celestia S. Higano, MD, FACP (lead moderator), and Charles J. Ryan, MD

8:25 PM - 8:30 PM  Final Faculty Comments and Audience Question and Answer Session –  Celestia S. Higano, MD, FACP (lead moderator), and Charles J. Ryan, MD 

Events

Date / Time
Event Details

Faculty

Program Director
Celestia S. Higano, MD

Professor
Departments of Medicine and Urology
University of Washington
Seattle, Washington

Faculty
Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director,
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors into the treatment of men with prostate cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with prostate cancer.

Learning Objectives 

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer including the poor prognosis in the absence of targeted treatment
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Interpret test results for predictive markers of PARP inhibitor benefit following evaluation of the available clinical evidence in CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Select PARP inhibitor treatment for appropriate men with prostate cancer
  • Manage adverse events and other barriers to adherence from PARP inhibitors
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.